Navigation Links
Mesa Labs Reports 18% Increase in Third Quarter Revenues
Date:2/5/2013

LAKEWOOD, Colo., Feb. 5, 2013 /PRNewswire/ -- Mesa Laboratories, Inc. (NASDAQ: MLAB) (we, us, our, "Mesa" or the "Company") today reported an 18 percent increase in revenues for the third quarter ended December 31, 2012.

Highlights:

  • Revenues for the third quarter increased 18 percent to $11,361,000 as compared to the same quarter last year
  • Revenues for the nine months ended December 31, 2012 increased 17 percent to $33,627,000 as compared to the same period last year
  • Net income for the nine months ended December 31, 2012 increased three percent to $5,891,000 as compared to the same period last year
  • Non-GAAP adjusted net income for the nine months ended December 31, 2012 increased 11 percent to $7,144,0001as compared to the same period last year
  • Revenues for the third quarter increased 18 percent to $11,361,000 as compared to $9,650,000 for the same quarter last year.  Net income for the third quarter decreased 22 percent to $1,543,000 or $0.44 per diluted share of common stock as compared to $1,987,000 or $0.57 per diluted share of common stock for the same quarter last year.  Net income for the third quarter was impacted by $526,000, before tax, of Chief Financial Officer transition costs, which are one-time in nature.

    Revenues for the nine months ended December 31, 2012 increased 17 percent to $33,627,000 as compared to $28,648,000 for the same period last year.  Net income for the nine months ended December 31, 2012 increased three percent to $5,891,000 or $1.67 per diluted share of common stock as compared to $5,720,000 or $1.66 per diluted share of common stock for the same period last year.

    On a non-GAAP basis (which excludes acquisition related intangible amortization, net of tax effects), adjusted net income for the third quarter decreased 11 percent to $1,974,000 or $0.56 per diluted share of common stock as compared to $2,217,000 or $0.63 per diluted share of common stock for the same quarter last year.  Adjusted net income for the third quarter was impacted by $526,000, before tax, of Chief Financial Officer transition costs, which are one-time in nature.  Adjusted net income for the nine months ended December 31, 2012 increased 11 percent to $7,144,000 or $2.03 per diluted share of common stock as compared to $6,427,000 or $1.86 per diluted share of common stock for the same period last year.

    "This was a challenging quarter for Mesa," said John J. Sullivan , President and Chief Executive Officer.  "While we experienced excellent revenue growth of 18% over this quarter last year, the growth was largely due to the acquisition of the Bios product line in May of 2012.  Excluding these Bios sales, our traditional businesses were up only one percent over this quarter last year.  Continuing growth of our consumable biological indicators business was offset by weakness in our capital equipment product lines, which was due to a tough economic environment for these products.  Certainly, we benefited this quarter from having a diverse suite of products to offer our customers."

    "While our gross margins held up very well this quarter and were unchanged from a year ago, non-recurring operational expenses negatively impacted our profitability and our net income decreased 22%," continued John Sullivan .  "The largest of these non-recurring expenses were those associated with the transition of our Chief Financial Officer position, which totaled $526,000, before tax, this quarter.  All of the costs associated with this transition were expensed in the current quarter, as required, even though some are non-cash, while others will be paid over a 12-month period.  Excluding the costs of our Chief Financial Officer transition, our non-GAAP adjusted net income would have risen by 4% in the third quarter."

    Revenues related to our Instruments division for the third quarter and nine months ended December 31, 2012 increased 26 percent and 28 percent, respectively, as compared to the same periods last year.  The increase in revenues was primarily due to the Bios acquisition.

    Revenues related to our Biological Indicators division for the third quarter and nine months ended December 31, 2012 increased nine percent and seven percent, respectively, as compared to the same periods last year.  The increase in revenues was due to organic growth.

    1 The non-GAAP measures of adjusted net income and adjusted net income per diluted share are defined to exclude the impacts of non-cash intangibles amortization, net of its tax effects. A reconciliation between these non-GAAP measures and their GAAP counterparts is set forth in the table below, along with additional information regarding their use.

    Financial SummaryStatements of Income(Unaudited)(Amounts in thousands, except per share data)Three months ended December 31,Nine months ended
    December 31,2012201120122011Revenues

    $ 11,361

    $ 9,650

    $ 33,627

    $ 28,648Cost of revenues

    4,414

    3,765

    12,976

    11,601  Gross profit

    6,947

    5,885

    20,651

    17,047Operating expenses

    4,483

    2,723

    11,478

    7,906  Operating income

    2,464

    3,162

    9,173

    9,141Other expense

    38

    31

    109

    130  Earnings before income taxes

    2,426

    3,131

    9,064

    9,011Income taxes

    883

    1,144

    3,173

    3,291  Net income

    $ 1,543

    $ 1,987

    $ 5,891

    $ 5,720Net income per share (basic)

    $ 0.46

    $ 0.60

    $ 1.76

    $ 1.74Net income per share (diluted)

    0.44

    0.57

    1.67

    1.66Weighted average common shares outstanding:Basic

    3,360

    3,286

    3,349

    3,280Diluted

    3,542

    3,498

    3,527

    3,454Balance Sheets(Amounts in thousands)December 31,
    2012(Unaudited)March 31,
    2012Cash and cash equivalents

    $   2,722

    $   7,191Other current assets

    13,836

    11,970  Total current assets

    16,558

    19,161Property, plant and equipment, net

    7,328

    7,266Other assets

    39,731

    24,269  Total assets

    $ 63,617

    $ 50,696Liabilities

    $ 13,518

    $   6,781Stockholders' equity

    50,099

    43,915  Total liabilities and stockholders' equity

    $ 63,617

    $ 50,696Reconciliation of Non-GAAP Measures(Unaudited)(Amounts in thousands, except per share data)Three months ended December 31,Nine months ended December 31,2012201120122011Net income

    $ 1,543

    $ 1,987

    $ 5,891

    $ 5,720Intangible amortization,

      net of taxes

    431

    230

    1,253

    707Adjusted net income

    $ 1,974

    $ 2,217

    $ 7,144

    $ 6,427Net income per share (basic)

    $ 0.59

    $ 0.67

    $ 2.13

    $ 1.96Net income per share (diluted)

    0.56

    0.63

    2.03

    1.86Weighted average common shares outstanding:Basic

    3,360

    3,286

    3,349

    3,280Diluted

    3,542

    3,498

    3,527

    3,454The non-GAAP measures of adjusted net income and adjusted net income per share presented in the reconciliation above are defined to exclude the impacts of non-cash intangibles amortization, net of their tax effects. The tax effect is calculated using the average corporate rate for that period multiplied by the amortization. We believe that excluding these acquisition related expenses provides the ability to understand the benefits of acquisitions based on their cash return.

    We provide non-GAAP net income and non-GAAP net income per share amounts in order to provide meaningful supplemental information regarding our operational performance. Our management uses non-GAAP measures to evaluate the performance of our business and to compensate employees. This information facilitates management's internal comparisons to our historical operating results as well as to the operating results of our competitors. Since management finds this measure to be useful, we believe that our investors can benefit by evaluating both non-GAAP and GAAP results.

    Our management recognizes that items such as amortization of intangibles can have a material impact on our net income. To gain a complete picture of all effects on our profit and loss from any and all events, management does (and investors should) rely upon the GAAP statements of income. The non-GAAP numbers focus instead upon our core operating business.

    Readers are reminded that non-GAAP measures are merely a supplement to, and not a replacement for, or superior to financial measures prepared according to GAAP. They should be evaluated in conjunction with the GAAP financial measures. It should be noted as well that our non-GAAP information may be different from the non-GAAP information provided by other companies.

    About Mesa Laboratories, Inc.

    We pursue a strategy of focusing primarily on quality control products, which are sold into niche markets that are driven by regulatory requirements. We prefer markets that have limited competition where we can establish a commanding presence and achieve high gross margins.  We are organized into two divisions across four physical locations.  Our Instruments division designs, manufactures and markets quality control instruments and disposable products utilized in connection with the healthcare, pharmaceutical, food and beverage, medical device, industrial hygiene, semiconductor and petrochemical industries.  Our Biological Indicators division manufactures and markets biological indicators and distributes chemical indicators used to assess the effectiveness of sterilization processes, including steam, gas, hydrogen peroxide and radiation, in the hospital, dental, medical device and pharmaceutical industries.

    Forward Looking Statements

    This press release may contain information that constitutes "forward-looking statements." Generally, the words "believe," "expect," "intend," "estimate," "anticipate," "project," "will" and similar expressions identify forward-looking statements, which generally are not historical in nature. However, the absence of these words or similar expressions does not mean that a statement is not forward-looking. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future — including statements relating to revenue growth and statements expressing general views about future operating results — are forward-looking statements. Management believes that these forward-looking statements are reasonable as and when made. However, caution should be taken not to place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from our historical experience and present expectations or projections. These risks and uncertainties include, but are not limited to, those described in our Annual Report on Form 10-K for the year ended March 31, 2012, and those described from time to time in our subsequent reports filed with the Securities and Exchange Commission.


    '/>"/>
    SOURCE Mesa Laboratories, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
    2. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
    3. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
    4. Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2012
    5. Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter
    6. CryoLife Reports Record Quarterly Revenues in First Quarter of 2012
    7. PAREXEL Reports Third Quarter Fiscal Year 2012 Financial Results
    8. Luminex Corporation Reports First Quarter 2012 Results
    9. Hospira Reports First-Quarter 2012 Results
    10. Endo Reports First Quarter Financial Results And Announces Return To Steady Supply Of OPANA® ER And Voltaren® Gel
    11. The Female Health Company Reports Second Quarter Operating Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Global MEMS Devices Medical Market Analysis 2016 - Forecast to ... The report contains up to date financial ... reliable analysis. Assessment of major trends with potential impact on ... dive analysis of market segmentation which comprises of sub markets, ...
    (Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 /PRNewswire/ ... Diabetes Tomorrow,s Leaders Scholarship is any indication, the future ... today online at www.diabetesscholars.org by the Diabetes ... stand in the way of academic and community service ... scholarship program since 2012, and continues to advocate for ...
    (Date:6/23/2016)... June 23, 2016 Research and ... Procedure Volumes: Global Analysis (United States, China, Japan, Brazil, ... report to their offering. ... for healthcare business planners, provides surgical procedure volume data ... trends with an in-depth analysis of growth drivers and ...
    Breaking Medicine Technology:
    (Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs ... College of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. ... treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. ...
    (Date:6/25/2016)... ... 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned ... the David Geffen School of Medicine at UCLA. He trained in Internal Medicine at ... fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity ...
    (Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
    (Date:6/24/2016)... ... June 24, 2016 , ... ... Scientific Sessions in Dallas that it will receive two significant new grants to ... came as PHA marked its 25th anniversary by recognizing patients, medical professionals and ...
    (Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief ... a minimum wage raise to $12 an hour by 2020 and then adjusting it yearly ... lost value of the minimum wage, assure the wage floor does not erode again, and ...
    Breaking Medicine News(10 mins):